Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of iEPCs in Acute Ischemic Stroke
NCT05993884Phase 1Completed
- Sponsor
- Allife Medical Science and Technology
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALF-202 in ischemic stroke (4 cohorts), sponsored by Allife Medical Science and Technology. Primary endpoint: Incidence and severity of adverse events after iEPCs infusion at 1 year. Started Aug 2023; status: completed.
02
Drugs
ALF-202
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05993884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993884.